InfuSystem beats Q3 profit estimates on oncology, wound care growth
Overview
US healthcare service provider's preliminary Q3 revenue rose 3%, slightly beating analyst expectations
Adjusted EPS for Q3 was $0.15, beating analyst expectations
Company reaffirmed full-year 2026 guidance
Outlook
Company reaffirms 2026 pro-forma revenue growth guidance of 6% to 8%
Company expects 2026 Adjusted EBITDA margin in the low-to-mid 20% range
Company expects additional investments in workflow automation and process improvements in Q4 2026
Result Drivers
ONCOLOGY AND WOUND CARE - Co said Q3 growth was driven by higher Oncology revenue and strong Wound Care performance, including compression therapy product lines
CONTRACT RESTRUCTURING - Restructuring of GE Healthcare contract reduced costs more than revenue, improving profitability and margins
ERP IMPLEMENTATION - Lower ERP project expenses contributed to reduced general and administrative costs
Company press release:
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | Slight Beat* | $37.59 mln | $37.28 mln (3 Analysts) |
Q3 EPS | Beat | $0.15 | $0.13 (3 Analysts) |
Q3 Net Income | Beat | $3.16 mln | $2.79 mln (2 Analysts) |
Q3 Operating Income | Beat | $4.75 mln | $4.15 mln (2 Analysts) |
Q3 Pretax Profit | Beat | $4.54 mln | $3.86 mln (2 Analysts) |
Q3 Gross Profit | $21.73 mln |
*Applies to a deviation of less than 1%; not applicable for per-share numbers.
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for InfuSystem Holdings Inc is $17.75, about 35% above its November 4 closing price of $13.15
The stock recently traded at 24 times the next 12-month earnings vs. a P/E of 18 three months ago
Reuters Recommended Reads
Nov 4 - Option Care Health Q3 revenue slightly beats estimates
Nov 3 - Senior care provider InnovAge's Q1 revenue beats as participants increase
Nov 4 - Ardent Health Q3 revenue beats analyst estimates
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)